Research programme: IPL5 series - Aventis/Inflazyme

Drug Profile

Research programme: IPL5 series - Aventis/Inflazyme

Alternative Names: IPL5 series research programme - Aventis/Inflazyme; LSAIDs research programme - Aventis/Inflazyme; Research programme: LSAIDs - Aventis/Inflazyme

Latest Information Update: 15 Feb 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inflazyme Pharmaceuticals
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Inflammation

Most Recent Events

  • 15 Feb 2005 Inflazyme Pharmaceuticals is winding down its LSAIDs™ collaboration with sanofi-aventis
  • 30 Jul 2004 No development reported - Preclinical for Inflammation in Canada (unspecified route)
  • 24 Feb 2000 IPL 576 compounds are being investigated for potential in atopic dermatitis and allergic conjunctivitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top